As expected, the AEs were mainly gastrointestinal and, while one subject withdrew from the study because of nausea, the majority of events were mild, and all were mild to moderate, in severity
In this article, well explore what ODTs are, their benefits, formulation challenges, manufacturing techniques, and regulatory considerations
Were committed to providing real solutions that address the pervasive gut-health challenges faced by millions of people, including those challenges brought on by GLP-1 drugs, said Tom Feeley, CEO for PanTheryx, the company behind Relesium
Listen to your body and adjust intensity as needed